Identifying a Heterogeneous Effect of Atrial Fibrillation Screening in Older Adults: A Secondary Analysis of the VITAL-AF Trial
- 1 July 2025
- journal article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (7) , e011482
Abstract
BACKGROUND: One-time atrial fibrillation (AF) screening trials in older adults have produced mixed results. In a secondary analysis of the VITAL-AF trial, we aimed to identify a subset of people in whom such screening is effective, using effect-based and risk-based approaches. METHODS: The VITAL-AF trial was a cluster-randomized trial of 1-time, 30-second single-lead ECG screening during primary care visits. It enrolled adults aged ≥65 years in 16 Massachusetts General Hospital primary care practices (2018–2019). In this secondary analysis, we tested 2 approaches to identify subgroups where screening is effective. First, we developed an effect-based model using T-learner, a causal inference approach that estimates screening effects by separately training 2 predictive models—one for screening and one for usual care—and then compares their predictions for each individual. Second, we used a validated AF risk model (Cohorts for Heart and Aging Research in Genomic Epidemiology AF) to test for heterogeneous screening effectiveness. We assessed AF screening effectiveness by quartile of predicted effect and predicted AF risk and determined their correlation. RESULTS: The study included 29 656 participants (mean±SD age 74±7 years, 59% women). In the highest quartile of predicted screening effect, AF diagnosis rates were higher in the screening versus the usual care group (4.00 versus 2.88 per 100 person-years, rate difference 1.12 [95% CI, 0.11–2.13] per 100 person-years). In the highest quartile of predicted AF risk, AF diagnosis rates were also higher in the screening versus the usual care group (5.55 versus 4.23 per 100 person-years, rate difference 1.32 [95% CI, 0.14–2.50] per 100 person-years). Predicted screening effect and predicted AF risk were weakly correlated (Spearman correlation coefficient, 0.23). CONCLUSIONS: One-time screening was associated with increased AF diagnoses in the top quartile of both predicted screening effect and predicted AF risk. Because predicted effect and risk were only weakly correlated, future AF screening efforts should include both high-effect and high-risk individuals.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Individualized Treatment Effects of Oxygen Targets in Mechanically Ventilated Critically Ill AdultsJAMA, 2024
- Using Effect Scores to Characterize Heterogeneity of Treatment EffectsJAMA, 2024
- Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19JAMA, 2023
- Toward Personalizing CareJAMA, 2023
- Screening for Atrial FibrillationJAMA, 2022
- Heterogeneity of Treatment EffectJAMA, 2021
- Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After StrokeJAMA, 2021
- Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trialAmerican Heart Journal, 2019
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA, 2016
- An Introduction to Statistical Learning2013